Ashland posts preliminary $16M Q4 FY2026 net loss
A stronger U.S. dollar is expected to reduce fiscal 2027 sales by approximately $20-$25 million and Adjusted EBITDA by $7-$10 million.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Ashland Inc. (ASH) reported preliminary fourth-quarter fiscal 2026 sales of $498 million, up 4% year over year, and a net loss of $16 million versus net income of $32 million. Adjusted EBITDA was $121 million versus $119 million; operating cash flow was $90 million versus $40 million, and Ongoing Free Cash Flow was $74 million versus $52 million. Results are preliminary until Ashland files its Form 10-K.
For fiscal 2026, sales were $1.863 billion and Adjusted EBITDA was $385 million, versus $401 million in fiscal 2025. Net income was $4 million versus a net loss of $845 million; fiscal 2025 included a $706 million noncash goodwill impairment and a $175 million Avoca-related impairment and sale adjustment. Ashland ended fiscal 2026 with $480 million of cash, $976 million of total liquidity, $891 million of net debt and 2.3x net leverage.
Fiscal 2027 outlook calls for sales of $1,905-$1,975 million and Adjusted EBITDA of $405-$435 million. Ongoing Free Cash Flow conversion is expected to be greater than 40 percent of Adjusted EBITDA, with capital expenditures of up to approximately $140 million.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointFiscal 2026 operating cash flow was $385 million, versus $134 million.
- Moderate pointFiscal 2026 Ongoing Free Cash Flow was $232 million, versus $127 million.
- Moderate pointLife Sciences Adjusted EBITDA increased 16% to $64 million.
- Moderate pointPersonal Care Adjusted EBITDA increased 14% to $49 million.
Negative
- Moderate pointFourth-quarter net results were a $16 million loss, versus $32 million income.
- Moderate pointSpecialty Additives Adjusted EBITDA fell 31% to $20 million in the quarter.
8-K Event Classification
Key Figures
Key Terms
Adjusted EBITDA financial
Ongoing Free Cash Flow Conversion financial
working capital financial
unfavorable absorption financial
Earnings Snapshot
Fiscal 2027 sales of $1,905 million to $1,975 million; Adjusted EBITDA of $405 million to $435 million; Ongoing Free Cash Flow conversion greater than 40% of Adjusted EBITDA; capital expenditures of up to approximately $140 million.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were ASH's fourth-quarter fiscal 2026 results?
What is ASH's fiscal 2027 outlook?
How could currency affect Ashland's fiscal 2027 outlook?
How did ASH's segments perform on Adjusted EBITDA in the fourth quarter?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: |
|
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On November 3, 2026, Ashland Inc. (“Ashland”) announced preliminary fourth quarter and fiscal year 2026 results and fiscal year 2027 outlook results, which are discussed in more detail in the news release (the “News Release”) attached to this Current Report on Form 8-K (“Form 8-K”) as Exhibit 99.1, which is incorporated herein by reference into this Item 2.02.
Item 7.01 Regulation FD Disclosure.
On November 3, 2026, Ashland will make available the News Release on the “Investor Center” section of Ashland’s website located at http://investor.ashland.com.
Item 9.01 Financial Statements and Exhibits.
(d) |
|
Exhibits |
|
|
|
99.1 |
|
News Release dated November 3, 2026. |
|
|
|
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL Document). |
In connection with the disclosures set forth in Items 2.02 and 7.01 above, the information in this Form 8-K, including the exhibit attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such section. The information in this Form 8-K, including the exhibit, shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any incorporation by reference language in any such filing. This Form 8-K will not be deemed an admission as to the materiality of any information in this Form 8-K that is required to be disclosed solely by Regulation FD.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
ASHLAND INC. |
|
|
|
|
Date: |
November 3, 2026 |
By: |
/s/ William C. Whitaker |
|
|
|
William C. Whitaker |
Exhibit 99.1
Ashland reports fourth quarter and full-year fiscal 2026 results and issues outlook for fiscal 2027
WILMINGTON, Del., November 3, 2026 – Ashland Inc. (NYSE: ASH) today announced financial results1 for the fourth quarter of fiscal year 2026, which ended September 30, 2026, together with its fiscal year 2026 results summary and full-year fiscal 2027 outlook. Ashland, a global additives and specialty ingredients company, holds leadership positions in high-quality, consumer-focused markets including pharmaceuticals, personal care and architectural coatings.
“Ashland closed fiscal 2026 with strong commercial performance across our higher-growth Life Sciences and Personal Care businesses, as well as coatings and performance specialties within Specialty Additives, and improved profitability in Intermediates,” said Guillermo Novo, chair and chief executive officer, Ashland. “Life Sciences delivered four percent sales growth, and pharma achieved its sixth consecutive quarter of year-over-year volume growth, with broad gains across regions and continued momentum from our globalize and innovate strategies. Personal Care generated another quarter of strong performance, with eight percent sales growth, including double-digit growth in biofunctional actives, microbial protection and hair care, and high-single-digit growth in skin care. Specialty Additives delivered nine percent sales growth in coatings and fourteen percent sales growth in performance specialties, reflecting share gains across all regions. These gains were offset by soft end-market demand in energy and resources and lower construction volumes resulting from deliberate portfolio actions.”
"Our globalize and innovate strategies exceeded their full-year targets, driven by deep customer engagement and successful commercialization," said Guillermo Novo, chair and chief executive officer,
1
Ashland. “Despite raw material and freight volatility, our teams executed well, with pricing actions recovering higher raw material costs. We have completed the critical investments needed to support improved productivity at our plants. We also generated healthy cash flow, further strengthening our financial flexibility as we enter fiscal 2027."
Novo continued, "Our priorities are clear: improve operating performance, drive productivity across our network, maintain pricing discipline, build on our commercial momentum and continue to scale our globalize and innovate initiatives. The strategic foundations are in place, and our focus is on execution to deliver improved profitability and long-term value creation."
Fourth-quarter sales were $498 million, up four percent from $478 million in the prior-year quarter. Sales volumes increased three percent, led by Pharma, Personal Care, Coatings and Performance Specialties. Pricing increased two percent, covering raw material cost inflation across all business units. Foreign currency movements reduced sales by approximately $3 million, or one percent.
Net loss was $16 million, compared with net income of $32 million in the prior-year quarter. Loss from continuing operations was $17 million, or ($0.36) per diluted share, compared with income from continuing operations of $33 million, or $0.73 per diluted share, in the prior-year quarter. Adjusted Income from Continuing Operations Excluding Intangibles Amortization Expense was $52 million, up from $50 million, or $1.12 per diluted share versus $1.08 in the prior-year quarter. Adjusted Operating Income was $77 million, up from $71 million in the prior-year quarter. Adjusted EBITDA was $121 million, up two percent from $119 million, and Adjusted EBITDA margin was 24.3 percent compared with 24.9 percent in the prior-year quarter. Double-digit Adjusted EBITDA growth in Life Sciences, Personal Care and Intermediates was partially offset by lower earnings in Specialty Additives, reflecting an unfavorable absorption impact, and higher unallocated corporate expenses. Foreign currency movements reduced Adjusted EBITDA by approximately $2 million.
Average diluted shares outstanding were 46 million in the fourth quarter, unchanged from the prior-year quarter.
Cash flows provided by operating activities were $90 million, up from $40 million in the prior-year quarter, driven primarily by lower working capital. Ongoing Free Cash Flow totaled $74 million versus $52 million in the prior-year quarter, representing Ongoing Free Cash Flow conversion of 61 percent versus 44 percent in the prior-year quarter, primarily reflecting the year-over-year reduction in working capital.
2
Reportable Segment Performance
To aid in the understanding of Ashland’s ongoing business performance, the results of Ashland’s reportable segments are described below on an adjusted basis. In addition, EBITDA and Adjusted EBITDA are reconciled to operating income in Table 4. Free Cash Flow, Ongoing Free Cash Flow and Adjusted Operating Income are reconciled in Table 6 and Adjusted Income from Continuing Operations, Adjusted Diluted Earnings Per Share and Adjusted Diluted Earnings Per Share Excluding Intangible Amortization Expense are reconciled in Table 7 of this news release. These adjusted results are considered non-GAAP financial measures. For a full description of the non-GAAP financial measures used, see the “Use of Non-GAAP Measures” section that further describes these adjustments below.
Life Sciences
Sales for the Life Sciences segment totaled $180 million in the fourth quarter, an increase of four percent compared with the prior-year quarter. Performance was driven by higher volumes, led by broad pharma growth across all major regions and technology platforms, including VP&D, cellulosics, injectables and film coatings. Pharma sales increased approximately six percent, representing the sixth consecutive quarter of year-over-year volume growth, supported by continued momentum from Ashland's globalize and innovate strategies. Nutrition sales declined slightly due to lower volumes. Prices increased approximately one percent compared with the prior year and covered cost inflation. Foreign currency movements reduced segment sales by approximately $1 million.
Adjusted Operating Income for the quarter was $50 million, up from $41 million in the prior-year quarter. Adjusted EBITDA totaled $64 million, an increase of 16 percent compared with $55 million in the prior-year quarter, and Adjusted EBITDA margin increased 380 basis points to 35.6 percent, the highest quarterly margin in the segment's history. The year-over-year increase was driven primarily by higher volumes, favorable product mix, pricing and cost performance. Foreign currency movements reduced Adjusted EBITDA by approximately $1 million during the quarter.
Personal Care
Personal Care sales in the fourth quarter were $163 million, an increase of eight percent compared with $151 million in the prior-year quarter. Performance reflected broad-based gains across the portfolio, including double-digit sales growth in biofunctional actives and microbial protection. Care Ingredients delivered strong results, led by double-digit growth in hair care and high-single-digit growth in skin care, while oral care and household sales declined by a low-single-digit percentage in aggregate. Performance was also strong across regions, with year-over-year sales growth in North America, Europe, China, Latin America and Rest of Asia. Prices increased modestly compared with the prior year and covered raw material cost inflation. Foreign currency movements reduced segment sales by approximately $1 million.
Adjusted Operating Income was $35 million, up 25 percent from $28 million in the prior-year quarter. Adjusted EBITDA was $49 million, up 14 percent from $43 million in the prior-year quarter, and Adjusted EBITDA margin increased 160 basis points to 30.1 percent. The year-over-year increase was driven primarily by higher sales volumes, favorable product mix, pricing and cost performance. Foreign currency movements had a negligible impact on Adjusted EBITDA.
3
Specialty Additives
Specialty Additives sales were $131 million in the fourth quarter, in line with the prior-year quarter. Coatings sales increased nine percent and Performance Specialties sales increased fourteen percent, reflecting favorable volumes, pricing and share gains across all regions, including a third consecutive quarter of year-over-year sales growth in China. These gains were offset by soft end-market demand in Energy and Resources and lower Construction volumes resulting from deliberate portfolio actions to prioritize higher-value applications. Prices increased approximately five percent compared with the prior-year quarter, covering raw material cost inflation. Foreign currency movements reduced segment sales by approximately $1 million.
Adjusted Operating Income was $5 million, compared with $12 million in the prior-year quarter, and Adjusted EBITDA was $20 million, down 31 percent from $29 million in the prior-year quarter. The year-over-year decline primarily reflected lower Hopewell productivity and related unfavorable absorption. Key productivity investments are now complete, with the focus on execution to increase production. Favorable price and mix partially offset these pressures. Foreign currency movements reduced Adjusted EBITDA by approximately $1 million.
Intermediates
Intermediates sales totaled $33 million in the fourth quarter, in line with the prior-year quarter. Merchant sales increased four percent to $24 million, offset by a $1 million decline in captive sales to $9 million. Favorable merchant mix, including higher NMP sales, and pricing more than offset lower merchant BDO volumes. Pricing increased approximately five percent compared with the prior-year quarter and covered raw material inflation. Foreign currency movements had a negligible impact on segment sales.
Adjusted Operating Income was $4 million, compared with $2 million in the prior-year quarter. Adjusted EBITDA was $6 million, up 20 percent from $5 million in the prior-year quarter, and Adjusted EBITDA margin increased 300 basis points to 18.2 percent. The year-over-year improvement was driven primarily by favorable merchant mix, pricing and cost performance, partially offset by lower volumes. Foreign currency movements had a negligible impact on Adjusted EBITDA during the quarter.
Unallocated & Other
Unallocated and other expense was $44 million, compared with $11 million in the prior-year quarter. The year-over-year increase primarily reflected higher restructuring charges and a cumulative translation adjustment associated with the liquidation of Ashland’s Argentine entity. Adjusted unallocated and other EBITDA expense was $18 million compared with $13 million in the prior-year quarter, primarily reflecting higher incentive and stock-based compensation expense.
Fiscal Year 2026 Results Summary
Sales were $1.863 billion, up two percent from $1.824 billion in the prior year. Excluding the impact of the previously announced Avoca divestiture, organic sales increased three percent. Commercial momentum strengthened throughout the year, with second-half sales increasing approximately six percent year over year. Life Sciences benefited from sustained pharma growth, Personal Care delivered broad-based growth across its higher-value businesses, and within Specialty Additives, Coatings and Performance Specialties
4
gained momentum as the year progressed. For the full year, volumes contributed approximately two percent to sales, pricing had a negligible impact, and foreign currency contributed approximately one percent. Pricing strengthened in the second half as actions were taken to offset cost inflation.
Net income was $4 million, compared with a net loss of $845 million in the prior year. Income from continuing operations was $25 million, or $0.55 per diluted share, compared with a loss from continuing operations of $822 million, or ($17.74) per diluted share, in fiscal 2025. The significant year-over-year improvement in reported results primarily reflected the absence of the $706 million non-cash goodwill impairment and $175 million Avoca-related impairment and sale adjustment recognized in fiscal 2025. Adjusted Income from Continuing Operations Excluding Intangibles Amortization Expense was $153 million, or $3.31 per diluted share, compared with $157 million, or $3.38 per diluted share, in the prior year.
Adjusted EBITDA was $385 million, compared with $401 million in fiscal 2025, including a $1 million year-over-year impact from the Avoca divestiture. Life Sciences and Personal Care delivered Adjusted EBITDA and margin growth, supported by resilient demand, favorable mix and strong execution. Within Specialty Additives, strong commercial performance in Coatings and Performance Specialties was more than offset by lower Hopewell productivity and the related unfavorable absorption impact. Intermediates profitability improved as the year progressed, supported by favorable merchant mix, pricing and cost performance. Overall Adjusted EBITDA margin was 20.7 percent, compared with 22.0 percent in fiscal 2025.
Cash flow from operating activities was $385 million, compared with $134 million in the prior year. Ongoing Free Cash Flow was $232 million, compared with $127 million in fiscal 2025. The year-over-year improvement primarily reflected lower working capital, driven by reduced inventory, as well as lower capital expenditures. Ashland ended fiscal 2026 with approximately $480 million of cash, $976 million of total liquidity and net debt of $891 million. Net leverage of 2.3x was within the company's long-term target range, providing significant financial flexibility entering fiscal 2027.
Throughout fiscal 2026, Ashland continued to advance its Execute, Globalize and Innovate priorities, strengthening its operating foundation while expanding opportunities for profitable growth. Execute initiatives delivered benefits across multiple pillars during the year, but Hopewell HEC productivity was below expectations. Globalize generated approximately $26 million of incremental sales, exceeding its fiscal 2026 target of $20 million. Innovate generated approximately $26 million of incremental sales, exceeding its fiscal 2026 target of $15 million. The company continued to advance its longer-term innovation portfolio toward customer validation, commercial launch and scaling. These initiatives position Ashland to deliver improved profitability, cash generation and sustainable long-term growth.
Financial Outlook
Ashland is issuing the following guidance for fiscal 2027, reflecting its current expectations for market conditions, business performance and continued execution of its strategic priorities.
5
Full-year fiscal 2027 guidance
Key planning assumptions
Fiscal 2027 strategic priority targets
"Our performance improved as the year progressed, reflecting the strength of our strategy and the commitment of our teams," concluded Novo. "Although the external markets remain challenging, we have a resilient portfolio with all businesses well positioned to focus on the factors within our control and deliver profitable growth.”
6
Conference Call Webcast
The company’s live webcast with securities analysts will include an executive summary and detailed remarks. The live webcast will take place at 9 a.m. ET on Wednesday, November 4, 2026. Simultaneously, the company will post a slide presentation in the Investor Relations section of its website at http://investor.ashland.com.
To access the call by phone, please go to this registration link and you will be provided with dial-in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time.
Following the live event, an archived version of the webcast and supporting materials will be available for 12 months at http://investor.ashland.com.
Use of Non-GAAP Measures
Ashland believes that by removing the impact of depreciation and amortization and excluding certain non-cash charges, amounts spent on interest and taxes, and certain other charges that are highly variable from year to year, EBITDA, Adjusted EBITDA, EBITDA Margin and Adjusted EBITDA Margin provide Ashland’s investors with performance measures that reflect the impact to operations from trends in changes in sales, margin and operating expenses, providing a perspective not immediately apparent from net income, operating income, net income margin, and operating income margin. The adjustments Ashland makes to derive the non-GAAP measures of EBITDA, Adjusted EBITDA, EBITDA Margin and Adjusted EBITDA Margin exclude items which may cause short-term fluctuations in net income and operating income and which Ashland does not consider to be the fundamental attributes or primary drivers of its business. EBITDA, Adjusted EBITDA, EBITDA Margin, and Adjusted EBITDA Margin provide disclosure on the same basis as that used by Ashland’s management to evaluate financial performance on a consolidated and reportable segment basis and provide consistency in our financial reporting, facilitate internal and external comparisons of Ashland’s historical operating performance and its business units, and provide continuity to investors for comparability purposes. EBITDA Margin and Adjusted EBITDA Margin are defined as EBITDA and Adjusted EBITDA divided by sales for the corresponding period.
Key items, which are set forth on Table 7 of this release, are defined as financial effects from significant transactions that, either by their nature or amount, have caused short-term fluctuations in net income and/or operating income which Ashland does not consider to reflect Ashland’s underlying business performance and trends most accurately. Further, Ashland believes that providing supplemental information that excludes the financial effects of these items in the financial results will enhance the investor’s ability to compare financial performance between reporting periods.
Tax-specific key items, which are set forth on Table 7 of this release, are defined as financial transactions, tax law changes or other matters that fall within the definition of key items as described above. These items relate solely to tax matters and would only be recorded within the income tax caption of the Statement of Consolidated Income. As with all key items, due to their nature, Ashland does not consider the financial effects of these tax-specific key items on net income to be the most accurate reflection of Ashland’s underlying business performance and trends.
7
The Free Cash Flow metrics enable Ashland to provide a better indication of the ongoing cash being generated that is ultimately available for both debt and equity holders as well as other investment opportunities. Unlike cash flow provided by operating activities, Free Cash Flow and Ongoing Free Cash Flow include the impact of capital expenditures from continuing operations and other significant items impacting Free Cash Flow, providing a more complete picture of current and future cash generation. Free Cash Flow, Ongoing Free Cash Flow, and Ongoing Free Cash Flow Conversion are non-GAAP liquidity measures that Ashland believes provide useful information to management and investors about Ashland’s ability to convert Adjusted EBITDA to ongoing Free Cash Flow. These liquidity measures are used regularly by Ashland’s stakeholders and industry peers to measure the efficiency at providing cash from regular business activity. Free Cash Flow, Ongoing Free Cash Flow, and Free Cash Flow Conversion have certain limitations, including that they do not reflect adjustments for certain non-discretionary cash flows such as mandatory debt repayments. The amount of mandatory versus discretionary expenditures can vary significantly between periods.
Adjusted Diluted Earnings Per Share is a performance measure used by Ashland and is defined by Ashland as earnings (loss) from continuing operations, adjusted for identified key items and divided by the number of outstanding diluted shares of common stock. Ashland believes this measure provides investors additional insights into operational performance by providing earnings and diluted earnings per share metrics that exclude the effect of the identified key items and tax specific key items.
The Adjusted Diluted Earnings Per Share Excluding Intangibles Amortization Expense metric enables Ashland to demonstrate the impact of non-cash intangibles amortization expense on earnings per share, in addition to key items previously mentioned. Ashland’s management believes this presentation is helpful to illustrate how previous acquisitions impact applicable period results.
Ashland does not quantitatively reconcile our guidance ranges for our non-GAAP measures to their most comparable GAAP measures in the Financial Outlook section of this news release. The guidance ranges for GAAP and non-GAAP financial measures reflect Ashland’s assessment of potential sources of variability in financial results and are informed by evaluation of multiple scenarios, many of which have interactive effects across several financial statement line items. Providing guidance for individual reconciling items between our non-GAAP financial measures and the comparable GAAP measures would imply a degree of precision and certainty in those reconciling items that is not a consistent reflection of our scenario-based process to prepare our guidance ranges. To the extent that a material change affecting the individual reconciling items between the company’s forward-looking non-GAAP and comparable GAAP financial measures is anticipated, the company has provided qualitative commentary in the Financial Outlook section of this news release for your consideration. However, as the impact of such factors cannot be predicted with a reasonable degree of certainty or precision, a quantitative reconciliation is not available without unreasonable effort.
About Ashland
Ashland Inc. (NYSE: ASH) is a global additives and specialty ingredients company with a conscious and proactive mindset for environmental, social and governance (ESG). The company serves customers in a wide range of consumer and industrial markets, including architectural coatings, construction, energy, food and
8
beverage, personal care and pharmaceuticals. Approximately 2,800 passionate, tenacious solvers – from renowned scientists and research chemists to talented engineers and plant operators – thrive on developing practical, innovative and elegant solutions to complex problems for customers in more than 100 countries. Visit ashland.com and ashland.com/ESG to learn more.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Ashland has identified some of these forward-looking statements with words such as “anticipates,” “believes,” “expects,” “estimates,” “is likely,” “predicts,” “projects,” “forecasts,” “objectives,” “may,” “will,” “should,” “plans” and “intends” and the negative of these words or other comparable terminology. Ashland may from time to time make forward-looking statements in its annual reports, quarterly reports and other filings with the U.S. Securities and Exchange Commission (“SEC”), news releases and other written and oral communications. These forward-looking statements are based on Ashland’s expectations and assumptions, as of the date such statements are made, regarding Ashland’s future operating performance, financial, operating cash flow and liquidity, as well as the economy and other future events or circumstances. These statements include, but are not limited to, expectations regarding the fiscal 2027 financial outlook and the key planning assumptions underlying that outlook, expected improvements in plant reliability and productivity, including the pace of improvement in Hopewell output and the timing of a Specialty Additives margin recovery; anticipated productivity and manufacturing optimization benefits, including those from the HEC and VP&D networks and the small plant consolidation initiative; Ashland’s fiscal 2027 Execute, Globalize and Innovate targets and the advancement of its innovation portfolio and Technology Platforms; Ashland’s commercial momentum and competitive positioning; Ashland’s cash generation and financial flexibility; and Ashland’s ability to deliver improved profitability and create long-term value.
Ashland’s expectations and assumptions include, without limitation, internal forecasts and analyses of current and future market conditions and trends, management plans and strategies, operating efficiencies and economic conditions (such as prices, supply and demand, cost of raw materials, and the ability to recover raw-material cost increases through price increases), and risks and uncertainties associated with the following: Ashland’s aggressive growth goals and the extent to which such goals may be impacted by a failure to optimize our tangible and intangible assets, a failure to identify and integrate acquisition targets, and any unexpected costs and liabilities associated with such acquisitions, and goodwill impairment; business disruptions stemming from natural, operational, and other catastrophic events, including disruptions to supply and logistics functions, manufacturing delays, and information technology system and network failures; climate change and related resource impacts; changes in consumer preferences and a reduction in demand for Ashland’s products; risks inherent in operating a global business, including tariffs and other trade policies, and geopolitical instability and armed conflict; economic downturns and disruptions in the financial markets; Ashland’s substantial indebtedness, including the possibility that such indebtedness and related restrictive covenants may adversely affect our future cash flows, limit our ability to repay debt and obtain future financing, place Ashland at a competitive disadvantage, and make us more vulnerable to interest rate increases; our ability to develop and market new products and remain competitive in the markets in which we operate; our ability to pass increases in the costs of energy and raw materials to customers and to fulfill our contractual requirements with customers and vendors; downward
9
pressures on prices and margins; the ability to attract and retain key employees, including across foreign jurisdictions where employment laws and business and cultural practices may differ, and to provide for effective succession planning; cybersecurity risks, including disruptions to or failures in Ashland’s information technology systems and networks, malicious cyberattacks, the inadvertent or accidental disclosure or loss of proprietary or sensitive information, and cyber risks related to Ashland’s external service providers and other third parties; risks related to Ashland’s use of artificial intelligence, including the potential for flawed or unreliable outputs, and the complexities and uncertainties in the legal and regulatory landscapes; Ashland’s ability to effectively protect and enforce its intellectual property rights; exposure to products liability claims; risks related to compliance with environmental, health, and safety regulations, including the potential for costly litigation, remediation, and settlement actions; exposure to pending and threatened asbestos-related litigation; changes in the legal and regulatory landscapes in which we operate; changes in taxation or adverse tax rulings; and, without limitation, risks and uncertainties affecting Ashland that are described in Ashland’s most recent Annual Report on Form 10-K (including Item 1A Risk Factors) filed with the SEC, which is available on Ashland’s website at http://investor.ashland.com or on the SEC’s website at http://www.sec.gov. Various risks and uncertainties may cause actual results to differ materially from those stated, projected or implied by any forward-looking statements. Ashland believes its expectations and assumptions are reasonable, but there can be no assurance that the expectations reflected herein will be achieved. Unless legally required, Ashland undertakes no obligation to update any forward-looking statements made in this news release whether as a result of new information, future events or otherwise.
1Financial results are preliminary until Ashland’s Form 10-K is filed with the U.S. Securities and Exchange Commission.
2The Ongoing Free Cash Flow metric excludes the impact of inflows and outflows from U.S. and Foreign Accounts Receivable Sales Program and payments related to restructuring and environmental and litigation-related matters in both the current-year and prior-year periods.
™ Trademark, Ashland or its subsidiaries, registered in various countries.
FOR FURTHER INFORMATION:
Investor Relations: |
Media Relations: |
Sandy Klugman |
Carolmarie C. Brown |
+1 (302) 594-7777 |
+1 (302) 995-3158 |
sandy.klugman@ashland.com |
ccbrown@ashland.com |
10
Ashland Inc. and Consolidated Subsidiaries STATEMENTS OF CONSOLIDATED INCOME (LOSS) (In millions except per share data - preliminary and unaudited) |
Table 1 |
|
Three months ended |
|
|
Year ended |
|
|
||||||||||||||
|
September 30 |
|
|
September 30 |
|
|
||||||||||||||
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
|
||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Sales |
$ |
|
498 |
|
|
$ |
|
478 |
|
|
$ |
|
1,863 |
|
|
$ |
|
1,824 |
|
|
Cost of sales |
|
|
319 |
|
|
|
|
319 |
|
|
|
|
1,262 |
|
|
|
|
1,275 |
|
|
GROSS PROFIT |
|
|
179 |
|
|
|
|
159 |
|
|
|
|
601 |
|
|
|
|
549 |
|
|
Selling, general and administrative expense |
|
|
113 |
|
|
|
|
76 |
|
|
|
|
377 |
|
|
|
|
344 |
|
|
Research and development expense |
|
|
14 |
|
|
|
|
13 |
|
|
|
|
55 |
|
|
|
|
54 |
|
|
Intangibles amortization expense |
|
|
14 |
|
|
|
|
15 |
|
|
|
|
60 |
|
|
|
|
63 |
|
|
Equity and other income |
|
|
2 |
|
|
|
|
2 |
|
|
|
|
4 |
|
|
|
|
4 |
|
|
Goodwill impairment |
|
|
- |
|
|
|
|
- |
|
|
|
|
- |
|
|
|
|
706 |
|
|
(Loss) income on divestitures, net |
|
|
(11 |
) |
|
|
|
4 |
|
|
|
|
(8 |
) |
|
|
|
(161 |
) |
|
OPERATING INCOME (LOSS) |
|
|
29 |
|
|
|
|
61 |
|
|
|
|
105 |
|
|
|
|
(775 |
) |
|
Net interest and other expense(a) |
|
|
21 |
|
|
|
|
- |
|
|
|
|
40 |
|
|
|
|
33 |
|
|
Other net periodic benefit (income) loss |
|
|
(1 |
) |
|
|
|
(3 |
) |
|
|
|
(4 |
) |
|
|
|
1 |
|
|
INCOME (LOSS) FROM CONTINUING OPERATIONS |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
BEFORE INCOME TAXES |
|
|
9 |
|
|
|
|
64 |
|
|
|
|
69 |
|
|
|
|
(809 |
) |
|
Income tax expense |
|
|
26 |
|
|
|
|
31 |
|
|
|
|
44 |
|
|
|
|
13 |
|
|
(LOSS) INCOME FROM CONTINUING OPERATIONS |
|
|
(17 |
) |
|
|
|
33 |
|
|
|
|
25 |
|
|
|
|
(822 |
) |
|
Income (loss) from discontinued operations, net of income taxes |
|
|
1 |
|
|
|
|
(1 |
) |
|
|
|
(21 |
) |
|
|
|
(23 |
) |
|
NET (LOSS) INCOME |
$ |
|
(16 |
) |
|
$ |
|
32 |
|
|
$ |
|
4 |
|
|
$ |
|
(845 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
DILUTED EARNINGS (LOSS) PER SHARE |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
(Loss) income from continuing operations |
$ |
|
(0.36 |
) |
|
$ |
|
0.73 |
|
|
$ |
|
0.55 |
|
|
$ |
|
(17.74 |
) |
|
Income (loss) from discontinued operations |
|
|
0.01 |
|
|
|
|
(0.02 |
) |
|
|
|
(0.46 |
) |
|
|
|
(0.49 |
) |
|
Net (loss) income |
$ |
|
(0.35 |
) |
|
$ |
|
0.71 |
|
|
$ |
|
0.09 |
|
|
$ |
|
(18.23 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
AVERAGE DILUTED COMMON SHARES OUTSTANDING(b) |
|
|
46 |
|
|
|
|
46 |
|
|
|
|
46 |
|
|
|
|
46 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
SALES |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Life Sciences |
|
|
180 |
|
|
|
|
173 |
|
|
|
|
671 |
|
|
|
|
641 |
|
|
Personal Care |
|
|
163 |
|
|
|
|
151 |
|
|
|
|
592 |
|
|
|
|
577 |
|
|
Specialty Additives |
|
|
131 |
|
|
|
|
131 |
|
|
|
|
504 |
|
|
|
|
511 |
|
|
Intermediates |
|
|
33 |
|
|
|
|
33 |
|
|
|
|
135 |
|
|
|
|
137 |
|
|
Intersegment sales |
|
|
(9 |
) |
|
|
|
(10 |
) |
|
|
|
(39 |
) |
|
|
|
(42 |
) |
|
|
$ |
|
498 |
|
|
$ |
|
478 |
|
|
$ |
|
1,863 |
|
|
$ |
|
1,824 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
OPERATING INCOME (LOSS) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Life Sciences |
|
|
33 |
|
|
|
|
39 |
|
|
|
|
131 |
|
|
|
|
(262 |
) |
|
Personal Care |
|
|
35 |
|
|
|
|
26 |
|
|
|
|
101 |
|
|
|
|
90 |
|
|
Specialty Additives |
|
|
1 |
|
|
|
|
5 |
|
|
|
|
(12 |
) |
|
|
|
(338 |
) |
|
Intermediates |
|
|
4 |
|
|
|
|
2 |
|
|
|
|
11 |
|
|
|
|
8 |
|
|
Unallocated and other |
|
|
(44 |
) |
|
|
|
(11 |
) |
|
|
|
(126 |
) |
|
|
|
(273 |
) |
|
|
$ |
|
29 |
|
|
$ |
|
61 |
|
|
$ |
|
105 |
|
|
$ |
|
(775 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
11
Ashland Inc. and Consolidated Subsidiaries CONDENSED CONSOLIDATED BALANCE SHEETS (In millions - preliminary and unaudited) |
Table 2
|
|
September 30 |
|
|
September 30 |
|
||||||
|
2026 |
|
|
2025 |
|
||||||
ASSETS |
|
|
|
|
|
|
|
|
|
||
Current assets |
|
|
|
|
|
|
|
|
|
||
Cash and cash equivalents |
$ |
|
|
480 |
|
|
$ |
|
|
215 |
|
Accounts receivable, net |
|
|
|
266 |
|
|
|
|
|
242 |
|
Inventories |
|
|
|
482 |
|
|
|
|
|
568 |
|
Other assets |
|
|
|
108 |
|
|
|
|
|
180 |
|
Total current assets |
|
|
|
1,336 |
|
|
|
|
|
1,205 |
|
|
|
|
|
|
|
|
|
|
|
||
Noncurrent assets |
|
|
|
|
|
|
|
|
|
||
Property, plant and equipment |
|
|
|
|
|
|
|
|
|
||
Cost |
|
|
|
3,304 |
|
|
|
|
|
3,355 |
|
Accumulated depreciation |
|
|
|
2,170 |
|
|
|
|
|
2,154 |
|
Net property, plant and equipment |
|
|
|
1,134 |
|
|
|
|
|
1,201 |
|
|
|
|
|
|
|
|
|
|
|
||
Goodwill |
|
|
|
698 |
|
|
|
|
|
705 |
|
Intangibles, net |
|
|
|
498 |
|
|
|
|
|
563 |
|
Operating lease assets, net |
|
|
|
99 |
|
|
|
|
|
103 |
|
Restricted investments |
|
|
|
248 |
|
|
|
|
|
297 |
|
Asbestos insurance receivable, net |
|
|
|
137 |
|
|
|
|
|
127 |
|
Deferred income taxes |
|
|
|
138 |
|
|
|
|
|
157 |
|
Other assets |
|
|
|
239 |
|
|
|
|
|
253 |
|
Total noncurrent assets |
|
|
|
3,191 |
|
|
|
|
|
3,406 |
|
|
|
|
|
|
|
|
|
|
|
||
Total assets |
$ |
|
|
4,527 |
|
|
$ |
|
|
4,611 |
|
|
|
|
|
|
|
|
|
|
|
||
LIABILITIES AND EQUITY |
|
|
|
|
|
|
|
|
|
||
Current liabilities |
|
|
|
|
|
|
|
|
|
||
Trade and other payables |
$ |
|
|
210 |
|
|
$ |
|
|
189 |
|
Accrued expenses and other liabilities |
|
|
|
220 |
|
|
|
|
|
213 |
|
Current portion of long-term debt |
|
|
|
4 |
|
|
|
|
|
- |
|
Current operating lease obligations |
|
|
|
18 |
|
|
|
|
|
21 |
|
Total current liabilities |
|
|
|
452 |
|
|
|
|
|
423 |
|
|
|
|
|
|
|
|
|
|
|
||
Noncurrent liabilities |
|
|
|
|
|
|
|
|
|
||
Long-term debt |
|
|
|
1,367 |
|
|
|
|
|
1,384 |
|
Asbestos litigation reserves |
|
|
|
385 |
|
|
|
|
|
389 |
|
Deferred income taxes |
|
|
|
24 |
|
|
|
|
|
31 |
|
Employee benefit obligations |
|
|
|
77 |
|
|
|
|
|
96 |
|
Operating lease obligations |
|
|
|
83 |
|
|
|
|
|
85 |
|
Other liabilities |
|
|
|
291 |
|
|
|
|
|
299 |
|
Total noncurrent liabilities |
|
|
|
2,227 |
|
|
|
|
|
2,284 |
|
|
|
|
|
|
|
|
|
|
|
||
Equity |
|
|
|
1,848 |
|
|
|
|
|
1,904 |
|
|
|
|
|
|
|
|
|
|
|
||
Total liabilities and equity |
$ |
|
|
4,527 |
|
|
$ |
|
|
4,611 |
|
12
Ashland Inc. and Consolidated Subsidiaries STATEMENTS OF CONSOLIDATED CASH FLOWS (In millions - preliminary and unaudited) |
Table 3
|
|
Three months ended |
|
|
Year ended |
|
||||||||||||||
|
September 30 |
|
|
September 30 |
|
||||||||||||||
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
||||||||
CASH FLOWS PROVIDED BY OPERATING ACTIVITIES FROM CONTINUING OPERATIONS |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Net (loss) income |
$ |
|
(16 |
) |
|
$ |
|
32 |
|
|
$ |
|
4 |
|
|
$ |
|
(845 |
) |
(Income) loss from discontinued operations, net of income taxes |
|
|
(1 |
) |
|
|
|
1 |
|
|
|
|
21 |
|
|
|
|
23 |
|
Adjustments to reconcile (loss) income from continuing operations to cash flows from operating activities |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Depreciation and amortization |
|
|
45 |
|
|
|
|
50 |
|
|
|
|
185 |
|
|
|
|
237 |
|
Original issue discount and debt issuance cost amortization |
|
|
2 |
|
|
|
|
2 |
|
|
|
|
8 |
|
|
|
|
7 |
|
Deferred income taxes |
|
|
3 |
|
|
|
|
68 |
|
|
|
|
7 |
|
|
|
|
73 |
|
Gain from sales of property, plant and equipment |
|
|
(3 |
) |
|
|
|
(5 |
) |
|
|
|
(5 |
) |
|
|
|
(16 |
) |
Equity income from affiliates |
|
|
- |
|
|
|
|
- |
|
|
|
|
(1 |
) |
|
|
|
- |
|
Stock based compensation expense |
|
|
5 |
|
|
|
|
2 |
|
|
|
|
18 |
|
|
|
|
14 |
|
Loss from excess tax deduction on stock based compensation |
|
|
- |
|
|
|
|
(3 |
) |
|
|
|
(1 |
) |
|
|
|
(3 |
) |
Income (loss) from restricted investments |
|
|
7 |
|
|
|
|
(17 |
) |
|
|
|
(21 |
) |
|
|
|
(33 |
) |
Loss on divestitures, net |
|
|
13 |
|
|
|
|
2 |
|
|
|
|
13 |
|
|
|
|
177 |
|
Goodwill impairment |
|
|
- |
|
|
|
|
- |
|
|
|
|
- |
|
|
|
|
706 |
|
Asset impairments |
|
|
18 |
|
|
|
|
- |
|
|
|
|
18 |
|
|
|
|
- |
|
Pension contributions |
|
|
(3 |
) |
|
|
|
(3 |
) |
|
|
|
(12 |
) |
|
|
|
(12 |
) |
Gain on pension and other postretirement plan remeasurements |
|
|
(2 |
) |
|
|
|
(4 |
) |
|
|
|
(7 |
) |
|
|
|
(3 |
) |
Change in operating assets and liabilities(a) |
|
|
22 |
|
|
|
|
(85 |
) |
|
|
|
158 |
|
|
|
|
(191 |
) |
Total cash flows provided by operating activities from continuing operations |
|
|
90 |
|
|
|
|
40 |
|
|
|
|
385 |
|
|
|
|
134 |
|
CASH FLOWS PROVIDED (USED) BY INVESTING ACTIVITIES FROM CONTINUING OPERATIONS |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Additions to property, plant and equipment |
|
|
(37 |
) |
|
|
|
(34 |
) |
|
|
|
(88 |
) |
|
|
|
(98 |
) |
Proceeds from disposal of property, plant and equipment |
|
|
2 |
|
|
|
|
5 |
|
|
|
|
6 |
|
|
|
|
16 |
|
Proceeds from sale of operations |
|
|
- |
|
|
|
|
- |
|
|
|
|
2 |
|
|
|
|
16 |
|
Proceeds from settlement of Company-owned life insurance contracts |
|
|
2 |
|
|
|
|
7 |
|
|
|
|
27 |
|
|
|
|
12 |
|
Company-owned life insurance payments |
|
|
(3 |
) |
|
|
|
(3 |
) |
|
|
|
(4 |
) |
|
|
|
(5 |
) |
Funds restricted for specific transactions |
|
|
- |
|
|
|
|
- |
|
|
|
|
(9 |
) |
|
|
|
(8 |
) |
Reimbursements from restricted investments |
|
|
22 |
|
|
|
|
21 |
|
|
|
|
74 |
|
|
|
|
62 |
|
Proceeds from sale of securities |
|
|
31 |
|
|
|
|
20 |
|
|
|
|
71 |
|
|
|
|
56 |
|
Purchases of securities |
|
|
(31 |
) |
|
|
|
(18 |
) |
|
|
|
(71 |
) |
|
|
|
(54 |
) |
Total cash flows provided (used) by investing activities from continuing operations |
|
|
(14 |
) |
|
|
|
(2 |
) |
|
|
|
8 |
|
|
|
|
(3 |
) |
CASH FLOWS USED BY FINANCING ACTIVITIES FROM CONTINUING OPERATIONS |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Repurchase of common stock |
|
|
- |
|
|
|
|
- |
|
|
|
|
- |
|
|
|
|
(100 |
) |
Debt issuance costs |
|
|
- |
|
|
|
|
- |
|
|
|
|
(2 |
) |
|
|
|
- |
|
Cash dividends paid |
|
|
(19 |
) |
|
|
|
(19 |
) |
|
|
|
(76 |
) |
|
|
|
(76 |
) |
Stock based compensation employee withholding taxes paid in cash |
|
|
(2 |
) |
|
|
|
- |
|
|
|
|
(3 |
) |
|
|
|
(3 |
) |
Total cash flows used by financing activities from continuing operations |
|
|
(21 |
) |
|
|
|
(19 |
) |
|
|
|
(81 |
) |
|
|
|
(179 |
) |
CASH PROVIDED (USED) BY CONTINUING OPERATIONS |
|
|
55 |
|
|
|
|
19 |
|
|
|
|
312 |
|
|
|
|
(48 |
) |
Cash used by discontinued operations |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Operating cash flows |
|
|
(15 |
) |
|
|
|
(13 |
) |
|
|
|
(46 |
) |
|
|
|
(40 |
) |
Effect of currency exchange rate changes on cash and cash equivalents(b) |
|
|
- |
|
|
|
|
2 |
|
|
|
|
(1 |
) |
|
|
|
3 |
|
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS |
|
|
40 |
|
|
|
|
8 |
|
|
|
|
265 |
|
|
|
|
(85 |
) |
CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD |
|
|
440 |
|
|
|
|
207 |
|
|
|
|
215 |
|
|
|
|
300 |
|
CASH AND CASH EQUIVALENTS - END OF PERIOD |
$ |
|
480 |
|
|
$ |
|
215 |
|
|
$ |
|
480 |
|
|
$ |
|
215 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
DEPRECIATION AND AMORTIZATION |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Life Sciences |
|
|
14 |
|
|
|
|
14 |
|
|
|
|
56 |
|
|
|
|
75 |
|
Personal Care |
|
|
14 |
|
|
|
|
16 |
|
|
|
|
60 |
|
|
|
|
65 |
|
Specialty Additives |
|
|
15 |
|
|
|
|
17 |
|
|
|
|
63 |
|
|
|
|
84 |
|
Intermediates |
|
|
2 |
|
|
|
|
3 |
|
|
|
|
5 |
|
|
|
|
13 |
|
Unallocated and other |
|
|
- |
|
|
|
|
- |
|
|
|
|
1 |
|
|
|
|
- |
|
|
$ |
|
45 |
|
|
$ |
|
50 |
|
|
$ |
|
185 |
|
|
$ |
|
237 |
|
13
Ashland Inc. and Consolidated Subsidiaries RECONCILIATION OF NON-GAAP DATA - ADJUSTED EBITDA (In millions - preliminary and unaudited) |
Table 4
|
|
|
Three months ended |
|
|||||||
|
|
September 30 |
|
|||||||
Adjusted EBITDA - Ashland Inc. |
|
2026 |
|
|
2025 |
|
||||
Net (loss) income |
|
$ |
|
(16 |
) |
|
$ |
|
32 |
|
Income tax expense |
|
|
|
26 |
|
|
|
|
31 |
|
Net interest and other income |
|
|
|
21 |
|
|
|
|
- |
|
Depreciation and amortization(a) |
|
|
|
45 |
|
|
|
|
49 |
|
EBITDA |
|
|
|
76 |
|
|
|
|
112 |
|
(Income) loss from discontinued operations, net of income taxes |
|
|
|
(1 |
) |
|
|
|
1 |
|
Gain on pension and other postretirement plan remeasurements |
|
|
|
(2 |
) |
|
|
|
(4 |
) |
Operating key items (see Table 5) |
|
|
|
48 |
|
|
|
|
10 |
|
Adjusted EBITDA |
|
$ |
|
121 |
|
|
$ |
|
119 |
|
|
|
|
|
|
|
|
|
|
||
Adjusted EBITDA - Life Sciences |
|
|
|
|
|
|
|
|
||
Operating income |
|
$ |
|
33 |
|
|
$ |
|
39 |
|
Add: |
|
|
|
|
|
|
|
|
||
Depreciation and amortization |
|
|
|
14 |
|
|
|
|
14 |
|
Operating key items (see Table 5) |
|
|
|
17 |
|
|
|
|
2 |
|
Adjusted EBITDA |
|
$ |
|
64 |
|
|
$ |
|
55 |
|
|
|
|
|
|
|
|
|
|
||
Adjusted EBITDA - Personal Care |
|
|
|
|
|
|
|
|
||
Operating income |
|
$ |
|
35 |
|
|
$ |
|
26 |
|
Add: |
|
|
|
|
|
|
|
|
||
Depreciation and amortization(a) |
|
|
|
14 |
|
|
|
|
15 |
|
Operating key items (see Table 5) |
|
|
|
- |
|
|
|
|
2 |
|
Adjusted EBITDA |
|
$ |
|
49 |
|
|
$ |
|
43 |
|
|
|
|
|
|
|
|
|
|
||
Adjusted EBITDA - Specialty Additives |
|
|
|
|
|
|
|
|
||
Operating income |
|
$ |
|
1 |
|
|
$ |
|
5 |
|
Add: |
|
|
|
|
|
|
|
|
||
Depreciation and amortization |
|
|
|
15 |
|
|
|
|
17 |
|
Operating key items (see Table 5) |
|
|
|
4 |
|
|
|
|
7 |
|
Adjusted EBITDA |
|
$ |
|
20 |
|
|
$ |
|
29 |
|
|
|
|
|
|
|
|
|
|
||
Adjusted EBITDA - Intermediates |
|
|
|
|
|
|
|
|
||
Operating income |
|
$ |
|
4 |
|
|
$ |
|
2 |
|
Add: |
|
|
|
|
|
|
|
|
||
Depreciation and amortization |
|
|
|
2 |
|
|
|
|
3 |
|
Adjusted EBITDA |
|
$ |
|
6 |
|
|
$ |
|
5 |
|
|
|
|
|
|
|
|
|
|
||
14
Ashland Inc. and Consolidated Subsidiaries SEGMENT COMPONENTS OF KEY ITEMS FOR APPLICABLE CONSOLIDATED INCOME (LOSS) STATEMENT CAPTIONS (In millions - preliminary and unaudited) |
Table 5
|
|
Three Months Ended September 30, 2026 |
|
|||||||||||||||||||||||||||
|
Life Sciences |
|
|
Personal Care |
|
|
Specialty Additives |
|
|
Intermediates |
|
|
Unallocated and other |
|
|
Total |
|
||||||||||||
OPERATING INCOME (LOSS) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Operating key items: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Asset impairments |
$ |
|
(16 |
) |
|
$ |
|
- |
|
|
$ |
|
(2 |
) |
|
$ |
|
- |
|
|
$ |
|
- |
|
|
$ |
|
(18 |
) |
Argentina liquidation cumulative translation adjustment |
|
|
- |
|
|
|
|
- |
|
|
|
|
- |
|
|
|
|
- |
|
|
|
|
(13 |
) |
|
|
|
(13 |
) |
Restructuring, separation and other costs |
|
|
- |
|
|
|
|
- |
|
|
|
|
- |
|
|
|
|
- |
|
|
|
|
(9 |
) |
|
|
|
(9 |
) |
Environmental reserve adjustments |
|
|
- |
|
|
|
|
- |
|
|
|
|
- |
|
|
|
|
- |
|
|
|
|
(5 |
) |
|
|
|
(5 |
) |
Other plant optimization costs |
|
|
(1 |
) |
|
|
|
- |
|
|
|
|
(2 |
) |
|
|
|
- |
|
|
|
|
- |
|
|
|
|
(3 |
) |
All other operating income (loss) |
|
|
50 |
|
|
|
|
35 |
|
|
|
|
5 |
|
|
|
|
4 |
|
|
|
|
(17 |
) |
|
|
|
77 |
|
Operating income (loss) |
|
|
33 |
|
|
|
|
35 |
|
|
|
|
1 |
|
|
|
|
4 |
|
|
|
|
(44 |
) |
|
|
|
29 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
NET INTEREST AND OTHER EXPENSE |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Key items |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
9 |
|
|
|
|
9 |
|
||||
All other net interest and other expense |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12 |
|
|
|
|
12 |
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
21 |
|
|
|
|
21 |
|
||||
OTHER NET PERIODIC BENEFIT INCOME |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Key items |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(2 |
) |
|
|
|
(2 |
) |
||||
All other net periodic benefit loss |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1 |
|
|
|
|
1 |
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1 |
) |
|
|
|
(1 |
) |
||||
INCOME TAX EXPENSE |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Tax effect of key items(a) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(4 |
) |
|
|
|
(4 |
) |
||||
Tax specific key items(b) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
7 |
|
|
|
|
7 |
|
||||
All other income tax expense |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
23 |
|
|
|
|
23 |
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
26 |
|
|
|
|
26 |
|
||||
(LOSS) INCOME FROM CONTINUING OPERATIONS |
$ |
|
33 |
|
|
$ |
|
35 |
|
|
$ |
|
1 |
|
|
$ |
|
4 |
|
|
$ |
|
(90 |
) |
|
$ |
|
(17 |
) |
|
Three Months Ended September 30, 2025 |
|
|||||||||||||||||||||||||||
|
Life Sciences |
|
|
Personal Care |
|
|
Specialty Additives |
|
|
Intermediates |
|
|
Unallocated and other |
|
|
Total |
|
||||||||||||
OPERATING INCOME (LOSS) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Operating key items: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Other plant optimization costs |
$ |
|
(2 |
) |
|
$ |
|
(1 |
) |
|
$ |
|
(7 |
) |
|
$ |
|
- |
|
|
$ |
|
- |
|
|
$ |
|
(10 |
) |
Restructuring, separation and other costs |
|
|
- |
|
|
|
|
- |
|
|
|
|
- |
|
|
|
|
- |
|
|
|
|
(4 |
) |
|
|
|
(4 |
) |
Nutraceutical business sale |
|
|
- |
|
|
|
|
- |
|
|
|
|
- |
|
|
|
|
- |
|
|
|
|
(1 |
) |
|
|
|
(1 |
) |
Environmental reserve adjustments |
|
|
- |
|
|
|
|
- |
|
|
|
|
- |
|
|
|
|
- |
|
|
|
|
(1 |
) |
|
|
|
(1 |
) |
Accelerated depreciation |
|
|
- |
|
|
|
|
(1 |
) |
|
|
|
- |
|
|
|
|
- |
|
|
|
|
- |
|
|
|
|
(1 |
) |
Tax credit |
|
|
- |
|
|
|
|
- |
|
|
|
|
- |
|
|
|
|
- |
|
|
|
|
3 |
|
|
|
|
3 |
|
Income on divestitures, net |
|
|
- |
|
|
|
|
- |
|
|
|
|
- |
|
|
|
|
- |
|
|
|
|
4 |
|
|
|
|
4 |
|
All other operating income (loss) |
|
|
41 |
|
|
|
|
28 |
|
|
|
|
12 |
|
|
|
|
2 |
|
|
|
|
(12 |
) |
|
|
|
71 |
|
Operating income (loss) |
|
|
39 |
|
|
|
|
26 |
|
|
|
|
5 |
|
|
|
|
2 |
|
|
|
|
(11 |
) |
|
|
|
61 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
NET INTEREST AND OTHER EXPENSE |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Key items |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(15 |
) |
|
|
|
(15 |
) |
||||
All other net interest and other expense |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
15 |
|
|
|
|
15 |
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
- |
|
|
|
|
- |
|
||||
OTHER NET PERIODIC BENEFIT LOSS |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Key items |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(4 |
) |
|
|
|
(4 |
) |
||||
All other net periodic benefit loss |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1 |
|
|
|
|
1 |
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(3 |
) |
|
|
|
(3 |
) |
||||
INCOME TAX EXPENSE |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Tax effect of key items(a) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2 |
|
|
|
|
2 |
|
||||
Tax specific key items(b) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
11 |
|
|
|
|
11 |
|
||||
All other income tax expense |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
18 |
|
|
|
|
18 |
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
31 |
|
|
|
|
31 |
|
||||
INCOME (LOSS) FROM CONTINUING OPERATIONS |
$ |
|
39 |
|
|
$ |
|
26 |
|
|
$ |
|
5 |
|
|
$ |
|
2 |
|
|
$ |
|
(39 |
) |
|
$ |
|
33 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
15
Ashland Inc. and Consolidated Subsidiaries RECONCILIATION OF CERTAIN NON-GAAP DATA (In millions - preliminary and unaudited) |
Table 6
|
|
|
Three months ended |
|
|
Year ended |
|
||||||||||||||
|
|
September 30 |
|
|
September 30 |
|
||||||||||||||
Free cash flows |
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
||||||||
Total cash flows provided by operating activities from continuing operations |
|
$ |
|
90 |
|
|
$ |
|
40 |
|
|
$ |
|
385 |
|
|
$ |
|
134 |
|
Adjustments: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Additions to property, plant and equipment |
|
|
|
(37 |
) |
|
|
|
(34 |
) |
|
|
|
(88 |
) |
|
|
|
(98 |
) |
Free Cash Flows |
|
$ |
|
53 |
|
|
$ |
|
6 |
|
|
$ |
|
297 |
|
|
$ |
|
36 |
|
Tax refund(a) |
|
|
|
- |
|
|
|
|
- |
|
|
|
|
(103 |
) |
|
|
|
- |
|
Cash (inflows) outflows from U.S. Accounts Receivable Sales Program(b) |
|
|
|
- |
|
|
|
|
1 |
|
|
|
|
(9 |
) |
|
|
|
12 |
|
Cash (inflows) outflows from Foreign Accounts Receivable Sales Program(c) |
|
|
|
3 |
|
|
|
|
19 |
|
|
|
|
(9 |
) |
|
|
|
6 |
|
Restructuring-related payments(d) |
|
|
|
6 |
|
|
|
|
11 |
|
|
|
|
23 |
|
|
|
|
34 |
|
Environmental and related litigation payments(e) |
|
|
|
12 |
|
|
|
|
15 |
|
|
|
|
33 |
|
|
|
|
39 |
|
Ongoing Free Cash Flow |
|
$ |
|
74 |
|
|
$ |
|
52 |
|
|
$ |
|
232 |
|
|
$ |
|
127 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Net (loss) income |
|
$ |
|
(16 |
) |
|
$ |
|
32 |
|
|
$ |
|
4 |
|
|
$ |
|
(845 |
) |
Adjusted EBITDA(f) |
|
$ |
|
121 |
|
|
$ |
|
119 |
|
|
$ |
|
385 |
|
|
$ |
|
401 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Operating Cash Flow Conversion(g) |
|
Not meaningful |
|
|
|
|
125 |
% |
|
|
|
9,625 |
% |
|
Not meaningful |
|
||||
Ongoing Free Cash Flow Conversion(h) |
|
|
|
61 |
% |
|
|
|
44 |
% |
|
|
|
60 |
% |
|
|
|
32 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
Three months ended |
|
|
Year ended |
|
||||||||||||||
|
|
September 30 |
|
|
September 30 |
|
||||||||||||||
Adjusted Operating Income |
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
||||||||
Operating income (loss) (as reported) |
|
$ |
|
29 |
|
|
$ |
|
61 |
|
|
$ |
|
105 |
|
|
$ |
|
(775 |
) |
Key items, before tax: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Environmental reserve adjustments |
|
|
|
5 |
|
|
|
|
1 |
|
|
|
|
33 |
|
|
|
|
34 |
|
Restructuring, separation and other costs |
|
|
|
9 |
|
|
|
|
4 |
|
|
|
|
23 |
|
|
|
|
22 |
|
Other plant optimization costs |
|
|
|
3 |
|
|
|
|
10 |
|
|
|
|
21 |
|
|
|
|
22 |
|
Asset impairments |
|
|
|
18 |
|
|
|
|
- |
|
|
|
|
18 |
|
|
|
|
- |
|
Argentina liquidation cumulative translation adjustment |
|
|
|
13 |
|
|
|
|
- |
|
|
|
|
13 |
|
|
|
|
- |
|
Accelerated depreciation |
|
|
|
- |
|
|
|
|
1 |
|
|
|
|
5 |
|
|
|
|
41 |
|
Goodwill impairment |
|
|
|
- |
|
|
|
|
- |
|
|
|
|
- |
|
|
|
|
706 |
|
Avoca business impairment and sale |
|
|
|
- |
|
|
|
|
- |
|
|
|
|
- |
|
|
|
|
175 |
|
Nutraceutical business impairment and sale |
|
|
|
- |
|
|
|
|
1 |
|
|
|
|
- |
|
|
|
|
1 |
|
Held for sale depreciation and amortization |
|
|
|
- |
|
|
|
|
- |
|
|
|
|
- |
|
|
|
|
(2 |
) |
Income on divestitures, net |
|
|
|
- |
|
|
|
|
(4 |
) |
|
|
|
(2 |
) |
|
|
|
(14 |
) |
Tax credit |
|
|
|
- |
|
|
|
|
(3 |
) |
|
|
|
(8 |
) |
|
|
|
(3 |
) |
Adjusted Operating Income (non-GAAP) |
|
$ |
|
77 |
|
|
$ |
|
71 |
|
|
$ |
|
208 |
|
|
$ |
|
207 |
|
16
Ashland Inc. and Consolidated Subsidiaries RECONCILIATION OF CERTAIN NON-GAAP DATA (In millions except per share data - preliminary and unaudited) |
Table 7
|
|
|
Three months ended |
|
|
Year ended |
|
||||||||||||||
|
|
September 30 |
|
|
September 30 |
|
||||||||||||||
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
||||||||
(Loss) income from continuing operations (as reported) |
|
$ |
|
(17 |
) |
|
$ |
|
33 |
|
|
$ |
|
25 |
|
|
$ |
|
(822 |
) |
Key items, before tax: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Environmental reserve adjustments |
|
|
|
5 |
|
|
|
|
1 |
|
|
|
|
33 |
|
|
|
|
34 |
|
Restructuring, separation and other costs |
|
|
|
9 |
|
|
|
|
4 |
|
|
|
|
23 |
|
|
|
|
22 |
|
Other plant optimization costs |
|
|
|
3 |
|
|
|
|
10 |
|
|
|
|
21 |
|
|
|
|
22 |
|
Asset impairments |
|
|
|
18 |
|
|
|
|
- |
|
|
|
|
18 |
|
|
|
|
- |
|
Argentina liquidation cumulative translation adjustment |
|
|
|
13 |
|
|
|
|
- |
|
|
|
|
13 |
|
|
|
|
- |
|
Accelerated depreciation |
|
|
|
- |
|
|
|
|
1 |
|
|
|
|
5 |
|
|
|
|
41 |
|
Goodwill impairment |
|
|
|
- |
|
|
|
|
- |
|
|
|
|
- |
|
|
|
|
706 |
|
Avoca business impairment and sale |
|
|
|
- |
|
|
|
|
- |
|
|
|
|
- |
|
|
|
|
175 |
|
Nutraceutical business impairment and sale |
|
|
|
- |
|
|
|
|
1 |
|
|
|
|
- |
|
|
|
|
1 |
|
Held for sale depreciation and amortization |
|
|
|
- |
|
|
|
|
- |
|
|
|
|
- |
|
|
|
|
(2 |
) |
Income on divestitures, net |
|
|
|
- |
|
|
|
|
(4 |
) |
|
|
|
(2 |
) |
|
|
|
(14 |
) |
Tax credit |
|
|
|
- |
|
|
|
|
(3 |
) |
|
|
|
(8 |
) |
|
|
|
(3 |
) |
Unrealized (gains) losses on securities |
|
|
|
9 |
|
|
|
|
(15 |
) |
|
|
|
(9 |
) |
|
|
|
(20 |
) |
Gain on pension and other postretirement plan remeasurements |
|
|
|
(2 |
) |
|
|
|
(4 |
) |
|
|
|
(7 |
) |
|
|
|
(3 |
) |
Key items, before tax |
|
|
|
55 |
|
|
|
|
(9 |
) |
|
|
|
87 |
|
|
|
|
959 |
|
Tax effect of key items(a) |
|
|
|
(4 |
) |
|
|
|
2 |
|
|
|
|
(14 |
) |
|
|
|
(62 |
) |
Key items, after tax |
|
|
|
51 |
|
|
|
|
(7 |
) |
|
|
|
73 |
|
|
|
|
897 |
|
Tax specific key items: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Valuation allowance |
|
|
|
7 |
|
|
|
|
8 |
|
|
|
|
7 |
|
|
|
|
9 |
|
Other and tax reform related activity |
|
|
|
- |
|
|
|
|
3 |
|
|
|
|
- |
|
|
|
|
22 |
|
Tax specific key items(b) |
|
|
|
7 |
|
|
|
|
11 |
|
|
|
|
7 |
|
|
|
|
31 |
|
Total key items |
|
|
|
58 |
|
|
|
|
4 |
|
|
|
|
80 |
|
|
|
|
928 |
|
Adjusted Income from Continuing Operations (non-GAAP) |
|
$ |
|
41 |
|
|
$ |
|
37 |
|
|
$ |
|
105 |
|
|
$ |
|
106 |
|
Intangibles amortization expense adjustment (net of tax)(c) |
|
|
|
11 |
|
|
|
|
13 |
|
|
|
|
48 |
|
|
|
|
51 |
|
Adjusted Income from Continuing Operations (non-GAAP) Excluding Intangibles Amortization Expense |
|
$ |
|
52 |
|
|
$ |
|
50 |
|
|
$ |
|
153 |
|
|
$ |
|
157 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
- Valuation allowance: Includes the impact from the release of certain foreign tax credit valuation allowances.
- Other and tax reform: Includes the impact from the remeasurement of foreign deferred tax balances resulting from the impact from rate changes for foreign jurisdictions and other tax law changes enacted during the year ended September 30, 2025.
17
Ashland Inc. and Consolidated Subsidiaries RECONCILIATION OF CERTAIN NON-GAAP DATA (In millions except per share data - preliminary and unaudited) |
Table 7 (Continued)
|
|
|
Three months ended |
|
|
Year ended |
|
||||||||||||||
|
|
September 30 |
|
|
September 30 |
|
||||||||||||||
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
||||||||
Diluted EPS from continuing operations (as reported) |
|
$ |
|
(0.36 |
) |
|
$ |
|
0.73 |
|
|
$ |
|
0.55 |
|
|
$ |
|
(17.74 |
) |
Key items, before tax: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Environmental reserve adjustments |
|
|
|
0.11 |
|
|
|
|
0.02 |
|
|
|
|
0.72 |
|
|
|
|
0.76 |
|
Restructuring, separation and other costs |
|
|
|
0.20 |
|
|
|
|
0.09 |
|
|
|
|
0.50 |
|
|
|
|
0.48 |
|
Other plant optimization costs |
|
|
|
0.06 |
|
|
|
|
0.23 |
|
|
|
|
0.46 |
|
|
|
|
0.48 |
|
Asset impairments |
|
|
|
0.38 |
|
|
|
|
- |
|
|
|
|
0.38 |
|
|
|
|
- |
|
Argentina liquidation cumulative translation adjustment |
|
|
|
0.28 |
|
|
|
|
- |
|
|
|
|
0.28 |
|
|
|
|
- |
|
Accelerated depreciation |
|
|
|
- |
|
|
|
|
0.02 |
|
|
|
|
0.10 |
|
|
|
|
0.89 |
|
Goodwill impairment |
|
|
|
- |
|
|
|
|
- |
|
|
|
|
- |
|
|
|
|
15.22 |
|
Avoca business impairment and sale |
|
|
|
- |
|
|
|
|
- |
|
|
|
|
- |
|
|
|
|
3.75 |
|
Nutraceutical business impairment and sale |
|
|
|
- |
|
|
|
|
0.02 |
|
|
|
|
- |
|
|
|
|
0.02 |
|
Held for sale depreciation and amortization |
|
|
|
- |
|
|
|
|
- |
|
|
|
|
- |
|
|
|
|
(0.04 |
) |
Income on divestitures, net |
|
|
|
- |
|
|
|
|
(0.09 |
) |
|
|
|
(0.04 |
) |
|
|
|
(0.30 |
) |
Tax credit |
|
|
|
- |
|
|
|
|
(0.07 |
) |
|
|
|
(0.17 |
) |
|
|
|
(0.07 |
) |
Unrealized (gains) losses on securities |
|
|
|
0.20 |
|
|
|
|
(0.33 |
) |
|
|
|
(0.19 |
) |
|
|
|
(0.42 |
) |
Gain on pension and other postretirement plan remeasurements |
|
|
|
(0.05 |
) |
|
|
|
(0.09 |
) |
|
|
|
(0.16 |
) |
|
|
|
(0.07 |
) |
Key items, before tax |
|
|
|
1.18 |
|
|
|
|
(0.20 |
) |
|
|
|
1.88 |
|
|
|
|
20.70 |
|
Tax effect of key items(a) |
|
|
|
(0.08 |
) |
|
|
|
0.04 |
|
|
|
|
(0.31 |
) |
|
|
|
(1.37 |
) |
Key items, after tax |
|
|
|
1.10 |
|
|
|
|
(0.16 |
) |
|
|
|
1.57 |
|
|
|
|
19.33 |
|
Tax specific key items: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Valuation allowance |
|
|
|
0.15 |
|
|
|
|
0.17 |
|
|
|
|
0.15 |
|
|
|
|
0.21 |
|
Other and tax reform related activity |
|
|
|
- |
|
|
|
|
0.07 |
|
|
|
|
- |
|
|
|
|
0.48 |
|
Tax specific key items(b) |
|
|
|
0.15 |
|
|
|
|
0.24 |
|
|
|
|
0.15 |
|
|
|
|
0.69 |
|
Total key items |
|
|
|
1.25 |
|
|
|
|
0.08 |
|
|
|
|
1.72 |
|
|
|
|
20.02 |
|
Adjusted Diluted EPS from Continuing Operations (non-GAAP) |
|
$ |
|
0.89 |
|
|
$ |
|
0.81 |
|
|
$ |
|
2.27 |
|
|
$ |
|
2.28 |
|
Intangibles amortization expense adjustment (net of tax)(c) |
|
|
|
0.23 |
|
|
|
|
0.27 |
|
|
|
|
1.04 |
|
|
|
|
1.10 |
|
Adjusted Diluted EPS from Continuing Operations (non-GAAP) Excluding Intangibles Amortization Expense |
|
$ |
|
1.12 |
|
|
$ |
|
1.08 |
|
|
$ |
|
3.31 |
|
|
$ |
|
3.38 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
- Valuation allowance: Includes the impact from the release of certain foreign tax credit valuation allowances.
- Other and tax reform: Includes the impact from the remeasurement of foreign deferred tax balances resulting from the impact from rate changes for foreign jurisdictions and other tax law changes enacted during the year ended September 30, 2025.
18
Ashland Inc. and Consolidated Subsidiaries RECONCILIATION OF CERTAIN NON-GAAP DATA (In millions - preliminary and unaudited) |
Table 8
|
|
|
Year ended |
|
|||||||
|
|
September 30 |
|
|||||||
Adjusted EBITDA - Ashland Inc. |
|
2026 |
|
|
2025 |
|
||||
Net income (loss) |
|
$ |
|
4 |
|
|
$ |
|
(845 |
) |
Income tax expense |
|
|
|
44 |
|
|
|
|
13 |
|
Net interest and other expense |
|
|
|
40 |
|
|
|
|
33 |
|
Depreciation and amortization(a) |
|
|
|
180 |
|
|
|
|
198 |
|
EBITDA |
|
|
|
268 |
|
|
|
|
(601 |
) |
Income (loss) from discontinued operations, net of income taxes |
|
|
|
21 |
|
|
|
|
23 |
|
Key items included in EBITDA: |
|
|
|
|
|
|
|
|
||
Environmental reserve adjustments |
|
|
|
33 |
|
|
|
|
34 |
|
Restructuring, separation and other costs |
|
|
|
23 |
|
|
|
|
22 |
|
Other plant optimization costs |
|
|
|
21 |
|
|
|
|
22 |
|
Asset impairments |
|
|
|
18 |
|
|
|
|
- |
|
Argentina liquidation cumulative translation adjustment |
|
|
|
13 |
|
|
|
|
- |
|
Accelerated depreciation |
|
|
|
5 |
|
|
|
|
41 |
|
Goodwill impairment |
|
|
|
- |
|
|
|
|
706 |
|
Avoca business impairment and sale |
|
|
|
- |
|
|
|
|
175 |
|
Nutraceutical business impairment and sale |
|
|
|
- |
|
|
|
|
1 |
|
Held for sale depreciation and amortization |
|
|
|
- |
|
|
|
|
(2 |
) |
Income on divestitures, net |
|
|
|
(2 |
) |
|
|
|
(14 |
) |
Tax credit |
|
|
|
(8 |
) |
|
|
|
(3 |
) |
Gain on pension and other postretirement plan remeasurements(b) |
|
|
|
(7 |
) |
|
|
|
(3 |
) |
Adjusted EBITDA(b) |
|
$ |
|
385 |
|
|
$ |
|
401 |
|
|
|
|
|
|
|
|
|
|
||
19
20